This study is a multicenter placebo-controlled double-blind randomized clinical trial. The design scheme is depicted in Figure 1. (see below). At the time of screening, all pentoxifylline-naïve participants must have been receiving angiotensin receptor blockers(ARB) per day for no less than 8 weeks and have stable renal function with serum creatinine elevation , 25% in the preceding 8 weeks. For patients taking maximal dose of angiotensin receptor blockers(ARB) for more than 8 weeks, randomization will be started after recruitment. For patients taking submaximal, fixed dose of angiotensin receptor blockers(ARB)for ≥ 8 weeks, with good BP(blood pressure), i.e., ≤ 130/80 mmHg, randomization can also be started after recruitment. However, for patients taking submaximal dose of angiotensin receptor blockers(ARB) with suboptimal BP, i.e., ?130/80 mmHg, patients can be recruited but will not be randomized until the dose of angiotensin receptor blockers(ARB) has been fixed for ≥ 8 weeks, or a ...
Angiotensin II receptor blockers (ARBs), also known as angiotensin II receptor antagonists , AT1 receptor antagonists or sartans, are a group of pharmaceuticals that modulate the renin-angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They block the activation of AT1 receptors, preventing the binding of angiotensin II. Angiotensin II receptor blockers are used primarily for the treatment of hypertension where the patient is intolerant of ACE inhibitor therapy. They do not inhibit the breakdown of bradykinin or other kinins, and are thus only rarely associated with the persistent dry cough and/or angioedema that limit ACE inhibitor therapy.[citation needed] More recently, they have been used for the treatment of heart failure in patients intolerant of ACE inhibitor therapy, in particular candesartan. Irbesartan and losartan have trial data showing benefit in ...
Angiotensin Receptor Blocker Angiotensin receptor blocker such as losartan, candensartan and valsartan are useful in treating patient with congestive heart failure and hypertension. Angiotensin receptor blocker will act by binding and blocking angioten
Background; Angiotensin receptor blocker (ARB) is being extensively used to control hypertension. But, there have been limited data whether ARB is associated with increased incidence of new-onset diabetes mellitus (DM) or impaired glucose intolerance (IGT).. Methods; We investigated total 13,561 patients (pts) that was glycerate hemoglobin level , 6.0% and fasting glucose level , 124 mg/dL (ARB therapy group=3421 and control group=9808) from January 2004 to February 2012. To adjust potential confounders, a propensity score matched analysis was performed using the logistic regression model. The primary end-point was the cumulative incidence of new-onset DM, IGT, and impaired fasting glucose (IFG). Also, multivariable cox-regression analysis by adjusted by aforementioned variables was performed to determine the impact of statin therapy on the incidence of new-onset DM, IGT, and IFG.. Results; Mean follow-up duration was 534±604 days in all-pt group, and 608±607 days in propensity score matching ...
Animation showing: Physiology of the renin angiotensin aldosteone system (RAAS). Mechanism of action of ACE inhibitors, Angiotensin II receptor blockers (ARBs).
Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174:773-85. 24687000 ...
OGIHARA Toshio , SARUTA Takao , SHIMAMOTO Kazuaki , MATSUOKA Hiroaki , RAKUGI Hiromi Hypertension research : clinical and experimental : official journal of the Japanese Society of Hypertension 31(2), 281-287, 2008-02-01 医中誌Web 参考文献36件 被引用文献2件 ...
Angiotensin receptor blockers (ARBs) are medications. They are most often prescribed to treat high blood pressure, but can be used to treat other conditions. This sheet tells you how ARBs work and how to use them effectively.
... are medications. They are most often prescribed to treat high blood pressure, but can be used to treat other conditions. This sheet tells you how ARBs work and how to use them effectively.
A randomized controlled study to compare the effects of angiotensin II type 1 receptor blockers (telmisartan vs candesartan vs valsartan) on the markers of cardiovascular risk in hypertensive patients with type 2 diabetes mellitus ...
Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study Prasad Bichu1, Ravi Nistala1, Asma Khan2, James R Sowers2, Adam Whaley-Connell11Divisions of Nephrology and Endocrinology; 2Department of Internal Medicine, University of Missouri-Columbia School of Medicine, Columbia Missouri, USAAbstract: Diabetic kidney disease is characterized by persistent albuminuria (>300 mg/dl or >200 μg/min) that is confirmed on at least 2 occasions 3 to 6 months apart, with a progressive decline in the glomerular filtration rate (GFR), elevated arterial blood pressure, and an increased risk for cardiovascular morbidity and mortality. Diabetic kidney disease is the leading cause of end stage renal disease (ESRD) prompting investigators to evaluate mechanisms by which to slow disease progression. One such mechanism is to block the activity of angiotensin II at the receptor site and agents that follow this mechanism are referred to as
Renin-angiotensin system inhibitors, specifically angiotensin II converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB), have confirmed renoprotective benefits in patients with proteinuria and hypertension. However, it remains controversial whether these agents are beneficial to kidney recipients. We conducted this meta-analysis to evaluate the effects of ACEI/ARB treatment on patient and allograft survival after kidney transplant. The PubMed, Embase and Cochrane Library databases were searched for eligible articles from before May 2016, and we included 24 articles (9 randomised controlled trials [RCTs] and 15 cohort studies with 54,096 patients), in which patient or graft survival was compared between an ACEI/ARB treatment arm and a control arm ...
In this systematic review, we identified a significantly increased risk of hyperkalaemia among people prescribed aliskiren (Rasilez; Novartis Pharmaceuticals, Switzerland) in combination with an ACE inhibitor or angiotensin receptor blocker compared with those prescribed monotherapy using aliskiren, an ACE inhibitor, or angiotensin receptor blocker. This risk was about 50% greater in those prescribed combination therapy than among those receiving ACE inhibitors or angiotensin receptor blocker monotherapy, and was about 70% greater in those prescribed combination therapy than among those receiving aliskiren monotherapy. We found no evidence of a significant difference in the risk of acute kidney injury between the study groups.. To date, no published systematic reviews or meta-analyses have evaluated the safety of combination therapy with aliskiren and ACE inhibitors or angiotensin receptor blockers. Previously published pooled analyses of the safety of aliskiren have provided discordant ...
We observed that two months of candesartan therapy significantly improved the percent flow-mediated dilator response to hyperemia and reduced levels of oxidant stress and inflammatory and impaired fibrinolysis markers in hypertensive patients, independent of lipoprotein and BP changes.. Our finding of improved endothelium-dependent vasomotor responsiveness is consistent with other groups results (23-25). Thus, Schiffrin et al. (24)demonstrated that, in contrast with atenolol, losartan corrected endothelial dysfunction in patients with essential hypertension, and Ghiadoni et al. (25)also demonstrated similar improvement in endothelial function with candesartan. We reasoned that candesartan might improve endothelium-dependent vasomotor responsiveness by reducing oxidant stress and augmenting NO bioactivity, considering that AII is a potent vasoconstrictor that also promotes oxidant stress. We observed that two months of candesartan therapy significantly reduced plasma levels of MDA, compared with ...
Primary Hypothesis:. To evaluate the combination of an angiotensin converting enzyme inhibitor (ACEI) with an angiotensin receptor blocker (ARB) vs. standard treatment with angiotensin receptor blocker on the progression of kidney disease in individuals with Type 2 diabetes and overt nephropathy.. The primary outcome is a composite endpoint of reduction in estimated GFR of 30 ml/min/1.73m*m in individuals with an estimated baseline GFR greater than or equal to 60 ml/min/1.73m*m; reduction in estimated GFR of greater than 50% in individuals with an estimated baseline GFR less than 60 mL/min/1.73m*m; progression to end-stage renal disease (defined as need for dialysis, renal transplant or an eGFR less than 15 ml/min/1.73m*m) or death.. Secondary outcome: a renal composite endpoint, defined as; reduction in estimated GFR of more than 50% (for individuals with a baseline estimated GFR less than 60 ml/min/1.73m*m); reduction in estimated GFR of more than 30 ml/min/1.73m*m (for individuals with a ...
The guidelines above are for the general population, but seniors health needs and benchmarks differ from those of younger individuals in many ways. While 130/80 mmHg is the generic threshold for beginning BP medications, there have been many disagreements among medical professionals regarding the threshold for older adults. Age, frailty and other comorbidities like diabetes and chronic kidney disease complicate this matter even further.. The Eighth Joint National Committee (JNC 8) issued guidelines in 2013 recommending that individuals over age 60 aim for a reading below 150/90 mmHg. The JNC 8 recommendation for patients of any age with diabetes or chronic kidney disease is to aim for BP readings below 140/90 mmHg. These are not hard and fast rules, though, because each seniors health needs are unique.. "The JNC 8 guidelines support what we geriatricians have believed for quite some time: many older adults are taking too much BP medication," says Dr. Leslie Kernisan, M.D., M.P.H. In addition ...
The FDA has approved azilsartan medoxomil (Edarbi), an oral angiotensin II receptor blocker (ARB) for hypertension, expanding the ranks of ARBs now available to U.S. patients.
This large population based study is the first to use data from routine clinical care to examine long term outcomes associated with changes in renal function after the start of ACEI/ARB treatment. It represents an important complement to clinical trials, the participants of which may not be representative of treated patients in clinical practice.6 The studys size and long follow-up also permitted examination of a full range of outcomes, beyond those evaluated in individual clinical trials. Importantly, this is the first study to examine the association with end stage renal disease, as clinical trials are rarely powered to examine this outcome.. Patients who had a greater fall in renal function after starting ACEI/ARB treatment had a higher proportion of comorbidities and concurrent drugs that are themselves associated with adverse renal outcomes. However, our findings were robust after adjustment for a range of potential confounders, including comorbidity, co-medication use, lifestyle factors, ...
The Food and Drugs Administration has completed a safety review of angiotensin receptor blockers (ARBs) after they were linked with an increased risk of cancer.. This review of 31 randomised clinical trials involving almost 156,000 participants, of whom 84,461 were treated with an ARB, found no increased risk. The review analysed the data for new cancer cases, cancer-related death, breast cancer, lung cancer and prostate cancer. There was no increase in risk for any of these outcomes.. Action: Clinicians and patients can be reassured by this safety review. It is important to note that the overall evidence still places ARBs are still second line to angiotensin converting enzyme inhibitors (ACEIs). ...
Chaoiya, C.; Berenguier, D.; Keating, S. M.; Naldi, A.; van Iersel, M. P.; Rodriguez, N.; Dräger, A.; Büchel, F.; Cokelaer, T.; Kowal, B. et al.; Wicks, B.; Gonçalves, E.; Dorier, J.; Page, M.; Monteiro, P. T.; Kamp von, A.; Xenarius , I.; de Jong, H.; Hucka, M.; Klamt, S.; Thieffrey, D.; Le Novère, N.; Saez-Rodriguez, J.; Helikar, T.: SBML qualitative models: a model representation format and infrastructure to foster interactions between qualitative modelling formlisms and tools. BMC Systems Biology 7, p. 135 (2013 ...
Valsartan is a potent, orally active angiotensin II receptor blocker and is widely used in the treatment of hypertension and chronic heart failure. Herein,
ACE inhibitors reduce the production of the enzyme angiotensin, which makes blood vessels constrict.Healthy Food: Top Blood Thinning Foods Before we begin mentioning blood thinning foods, there is a major thumb rule that should not be ignored.Blood clots stop the flow of blood to the heart, lungs, or brain and can cause a.. ACE (angiotensin-converting enzyme) inhibitors and angiotensin II receptor blockers (ARBs).The foods you choose to eat can affect your heart health in many ways. If you are on warfarin or another blood-thinning medication ...
Dom-Irbesartan: Irbesartan belongs to a family of medicines known as angiotensin II receptor blockers. These medicines are used to lower high blood pressure and work by relaxing blood vessels. Irbesartan is used to lower blood pressure and decrease the rate of the progression of kidney damage in patients with type 2 diabetes.
Auro-Irbesartan: Irbesartan belongs to a family of medicines known as angiotensin II receptor blockers. These medicines are used to lower high blood pressure and work by relaxing blood vessels. Irbesartan is used to lower blood pressure and decrease the rate of the progression of kidney damage in patients with type 2 diabetes.
Riva-Irbesartan: Irbesartan belongs to a family of medicines known as angiotensin II receptor blockers. These medicines are used to lower high blood pressure and work by relaxing blood vessels. Irbesartan is used to lower blood pressure and decrease the rate of the progression of kidney damage in patients with type 2 diabetes.
The new on this front at the European Society of Hypertension meeting in Oslo last week was that the addition of the VALUE data to the analysis removed the over-prevalence of new diagnosis cancers. Of related interest is that both beta-blockers and calcium-antagonists went through episodes when they were though to cause cancer, but where more data and more rigorous analysis disproved this. This is probably what we are facing with ARBs too, but that will of course take more data and more analysis. As of today, there is no indication to stop ARB treatment for fear of cancer.. ReplyDelete ...
Mint-Losartan: Losartan belongs to a family of medications known as angiotensin II receptor blockers. These medications are used in adults and children over the age of six to lower mild-to-moderate hypertension (high blood pressure).
Can you pick the Adrenergic Receptor Blockers Test your knowledge on this science quiz to see how you do and compare your score to others. Quiz by poorvichhabra
2017 The Author. Published by Oxford University Press for the Infectious Diseases Society of America. Background. Although statins, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are generally well tolerated, the impact of these therapies individually or in combination on the change in neurocognitive function in persons with human immunodeficiency virus infection is unknown. Methods. The study included participants in the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort participants not receiving a statin or ACEI/ARB within 30 days of first neurologic assessment (baseline), with assessments by NPZ-3 (z score of averaged Trailmaking A and B tests and digit symbol test [DST]) from ≥2 measurements. Marginal structural models estimated the causal effect of statin or ACEI/ARB initiation on neurocognitive function; initial constant slope was assumed during the first year of treatment and a second constant slope thereafter. Results. Of ...
Randomised controlled trial of a Calcium Channel or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Regime to Reduce Blood Pressure Variability following Ischaemic Stroke (CAARBS): a protocol for a feasibility study.
The role of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) reducing risk of cardiovascular events (CVEs) and preserving kidney function in patients with chronic kidney disease is well-documented. However, the efficacy and safety of these agents in dialysis patients is still a controversial issue. We systematically searched MEDLINE, Embase, Cochrane Library and Wanfang for randomized trials. The relative risk (RR) reductions were calculated with a random-effects model. Major cardiovascular events, changes in GFR and drug-related adverse events were analyzed. Eleven trials included 1856 participants who were receiving dialysis therapy. Compared with placebo or other active agents groups, ARB therapy reduced the risk of heart failure events by 33% (RR 0.67, 95% CI 0.47 to 0.93) with similar decrement in blood pressure in dialysis patients. Indirect comparison suggested that fewer cardiovascular events happened during treatment with ARB (0.77, 0.63 to 0.94). The
TY - JOUR. T1 - Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia. AU - Armstrong, Ehrin J.. AU - Chen, Debbie C.. AU - Singh, Gagan. AU - Amsterdam, Ezra A. AU - Laird, John R.. PY - 2015/6/5. Y1 - 2015/6/5. N2 - Angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are recommended for secondary prevention in peripheral artery disease, but their effectiveness in patients with critical limb ischemia (CLI) is uncertain. We reviewed 464 patients with CLI who underwent diagnostic angiography or endovascular intervention from 2006-2013 at a multidisciplinary vascular center. ACEI or ARB use was assessed at the time of angiography. Major adverse cardiovascular events (MACE), mortality, and major adverse limb events (MALE) were assessed during three-year follow-up. Propensity weighting was used to adjust for baseline differences between ...
Angiotensin-II receptor antagonists (or blockers) are a newer class of antihypertensive agents. These drugs are selective for angiotensin II (type 1 receptor); unlike angiotensin-converting enzyme inhibitors, they do not inhibit bradykinin metabolism or enhance prostaglandin synthesis. Angiotensin-II receptor antagonists are well tolerated. Cough occurs much less often with these agents than with angiotensin-converting enzyme inhibitors, and they do not adversely affect lipid profiles or cause rebound hypertension after discontinuation. Clinical trials indicate that angiotensin-II receptor antagonists are effective and safe in the treatment of hypertension. Their use in congestive heart failure and renal disease is under investigation.
TY - JOUR. T1 - Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease. AU - Qiao, Yao. AU - Shin, Jung Im. AU - Sang, Yingying. AU - Inker, Lesley A.. AU - Secora, Alex. AU - Luo, Shengyuan. AU - Coresh, Josef. AU - Alexander, G. Caleb. AU - Jackson, John W.. AU - Chang, Alex R.. AU - Grams, Morgan E.. PY - 2019/11/1. Y1 - 2019/11/1. N2 - Objective: To assess the patterns of angiotensin converting enzyme inhibitors and angiotensin receptor blockers (ACE-I/ARB) discontinuation in the setting of chronic kidney disease (CKD) progression in real-world clinical practice. Patients and Methods: We identified incident ACE-I/ARB users with a baseline estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73 m2 and without end-stage renal disease in the Geisinger Health System between January 1, 2004, and December 31, 2015. We investigated the associations of CKD stage, hospitalizations with and without acute kidney injury (AKI), serum ...
Reduce the impact of angiotensin II receptor blocker drugs recalls on your patients by switching them from ARB to other appropriate drug therapies.
Dr. James Lohr, Division of Nephrology, VAMC, 3495 Bailey Avenue, Buffalo, NY 14215. Phone: 716-862-3204; Fax: 716-862-6784; E-mail: James.Lohr{at}med.va.gov ...
Both angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) reduce angiotensin action. Angiotensin, a powerful hormone, has many actions, the most important of which is constriction of small blood vessels, leading to a rise in blood pressure and therefore in the pressure of blood within the glomerular capillaries in the kidneys. Lowering this pressure may well be the mechanism by which these drugs tend to slow progression of kidney failure.. The effects of ACEIs differ from those of ARBs in several important respects. It is even conceivable that taking drugs from both classes is more effective than taking just one or the other alone. Unfortunately, side-to-side comparisons of these two classes of drugs have not been performed, because the drug industry has no interest in such trials. These drugs are also effective in reducing urinary protein excretion in the nephrotic syndrome, and they also slow progression of chronic renal failure even when added to a ...
TY - JOUR. T1 - Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction. AU - Kostis, John. PY - 2019/7/1. Y1 - 2019/7/1. UR - http://www.scopus.com/inward/record.url?scp=85065221731&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85065221731&partnerID=8YFLogxK. U2 - https://doi.org/10.1177/1074248419841636. DO - https://doi.org/10.1177/1074248419841636. M3 - Letter. C2 - 31035789. VL - 24. JO - Journal of Cardiovascular Pharmacology and Therapeutics. JF - Journal of Cardiovascular Pharmacology and Therapeutics. SN - 1074-2484. IS - 4. ER - ...
Angiotensin-II receptor antagonists work in a similar way to ACE inhibitors. But instead of stopping the production of angiotensin II, they block its action. This allows the blood vessels to expand, improving blood flow and reducing blood pressure. Angiotensin II is a very potent chemical that causes muscles surrounding blood vessels to contract, thereby narrowing blood vessels. This narrowing increases the pressure within the vessels and can cause high blood pressure (hypertension). Angiotensin II receptor blockers (ARBs) are medications that block the action of angiotensin II by preventing angiotensin II from binding to angiotensin II receptors on blood vessels. As a result, blood vessels enlarge (dilate) and blood pressure is reduced. Reduced blood pressure makes it easier for the heart to pump blood and can improve heart failure. In addition, the progression of kidney disease due to high blood pressure or diabetes is slowed. ARBs have effects that are similar to angiotensin converting enzyme ...
The goal of this request was to estimate the number of prevalent users and dispensings of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) among pediatric pop
Renin-angiotensin system inhibitors, specifically angiotensin II converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB), have confirmed renoprotective benefits in patients with proteinuria and hypertension. However, it remains controversial whether these agents are beneficial to kidney recipients. We conducted this meta-analysis to evaluate the effects of ACEI/ARB treatment on patient and allograft survival after kidney transplant. The PubMed, Embase and Cochrane Library databases were searched for eligible articles from before May 2016, and we included 24 articles (9 randomised controlled trials [RCTs] and 15 cohort studies with 54,096 patients), in which patient or graft survival was compared between an ACEI/ARB treatment arm and a control arm ...
Initial studies suggested that angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and (possibly) aldosterone antagonists might either prevent new onset and recurrent atrial fibrillation (AF) or reduce the rate of ma
ACE inhibitors reduce the production of the enzyme angiotensin, which makes blood vessels constrict. ACE inhibitors allow blood vessels to expand so that blood can flow more easily and the heart can work more efficiently. Examples of commonly prescribed ACE inhibitors are benazepril, captopril, enalapril, lisinopril, and others.. Angiotensin II receptor blockers block the effects of angiotensin, preventing it from affecting the heart and blood vessels. Examples of angiotensin II receptor blockers are candesartan, losartan, telmisartan, valsartan, and others.. Pregnant women should not take ACE inhibitors or ARBs. These medicines can cause a risk of birth defects. If you have high blood pressure and plan to become pregnant or are pregnant, contact your healthcare provider right away.. ...
TY - JOUR. T1 - Angiotensin receptor blockers. T2 - Clinical relevance and new opportunities. AU - Volpe, Massimo. PY - 2012. Y1 - 2012. N2 - Effective treatment of high blood pressure (BP) is a key strategy for reducing the burden of hypertension-related cardiovascular diseases, ie, mainly stroke, myocardial infarction, heart failure, and cardiovascular death. Despite these well-established concepts, however, hypertension remains poorly controlled worldwide. In addition, patients treated for hypertension often remain at a higher risk as compared to the normotensive population, even when a satisfactory BP control is achieved. This is due to the concomitant presence of metabolic abnormalities and/or organ damage, thus accounting for the high or very high added cardiovascular risk profile often observed in patients with hypertension. An emerging strategy to improve general BP control and achieve this unmet target for cardiovascular disease prevention in patients with hypertension is represented by ...
Accumulated evidence suggests that an altered ambulatory blood pressure (BP) profile, particularly elevated nighttime BP, reflects target organ injury and is a better predictor of further cardiorenal risk than the clinic BP or daytime BP in hypertens
Looks at ARB medicines used to treat high blood pressure. Lists generic and brand names such as candesartan (Atacand) and irbesartan (Avapro). Covers how well they work and possible side effects. Warns against pregnant women taking ARBs. New Mexico, New Mexico
Looks at ARB medicines used to treat high blood pressure. Lists generic and brand names such as candesartan (Atacand) and irbesartan (Avapro). Covers how well they work and possible side effects. Warns against pregnant women taking ARBs. State of Nebraska, Nebraska
Abstract of Paper: Effect Of Angiotensin-II Receptor Blockade On Experimental Portal hypertension In Rabbits , Author: Sherif w. Mansour, Mohamed Abd El Homed and Mohamed Adel El-Sayed * , Year: 2003 , Faculty of Medicine, Benha University
Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS ...
Compare & find the top performing anti-Mouse (Murine) Angiotensin II Type-1 Receptor antibody for Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)).